ASH 2014: Dr Ian Flinn discusses the treatment of haematological malignancies with idelalisib - 101271

Spotlight
Video

ASH 2014: Dr Ian Flinn discusses the treatment of haematological malignancies with idelalisib

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses the selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta isoform (P110δ), idelalisib, in the management of haematological malignancies, including lymphoma and chronic lymphocytic leukaemia (CLL). Idelalisib is considered in combination with other therapies to enhance efficacy endpoints.
Shared By : EMJ
Posted on : 01/27/15
Added : 3 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.